663 results match your criteria Thrombocytosis Secondary


[A case of gout secondary to primary myelofibrosis].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1117-1119

Department of Rheumatology and Immunology,Peking University First Hospital, Beijing 100034, China.

A 52-year-old man was referred to our department with a 2-year history of polyarthritis. He was diagnosed as gout due to acute arthritis of bilateral feet dorsum 2 years ago,but he didn't receive any standard treatment. 1 year ago,there were more and more joints evolved during the gout attack, and many subcutaneous nodules occurred. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.

Eur J Haematol 2018 Nov 19. Epub 2018 Nov 19.

Department of Haematology, Odense University Hospital, Odense, Denmark.

Objective: Pulmonary hypertension (PH) has been reported to be associated with myeloproliferative neoplasms (MPN), affecting 5%-48% of MPN patients. With the aims to describe the prevalence of PH in Ph-MPN patients and explore the cause in identified subjects, we performed a prospective cohort study of Ph-MPN patients.

Method: Transthoracic echocardiography (TTE) was performed on all patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13197
Publisher Site
http://dx.doi.org/10.1111/ejh.13197DOI Listing
November 2018
9 Reads

Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.

Medicine (Baltimore) 2018 Nov;97(44):e13118

Department of Anesthesiology and Pain Medicine, Ulsan University Hospital, Ulsan University, Republic of Korea.

Rationale: Thrombosis is a major cause of morbidity in the perioperative period. Although many risk factors are known, activated protein C resistance is a prominent risk for thrombosis. Activated protein C resistance frequently occurs with recurrent thromboembolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221756PMC
November 2018
2 Reads

[Risk of thrombosis in reactive thrombocytosis].

Ned Tijdschr Geneeskd 2018 09 17;162. Epub 2018 Sep 17.

Onze Lieve Vrouwe Gasthuis, afd. Kindergeneeskunde, Amsterdam.

Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Read More

View Article

Download full-text PDF

Source
September 2018
3 Reads

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

J Clin Oncol 2018 Aug 28:JCO2018788414. Epub 2018 Aug 28.

Anna L. Godfrey, Jacob Grinfeld, and Anthony R. Green, Cambridge University Hospitals National Health Service (NHS) Foundation Trust; Peter J. Campbell and Jyoti Nangalia, Wellcome Trust Sanger Institute, Hinxton; Cathy MacLean, Julia Cook, Julie Temple, and Anthony R. Green, University of Cambridge; Anthony R. Green, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge; Georgina Buck, University of Oxford, Oxford; Bridget S. Wilkins and Claire N. Harrison, Guy's and St Thomas' NHS Foundation Trust, London; Keith Wheatley, University of Birmingham, Birmingham; Mary Frances McMullin, Queen's University Belfast, Belfast, United Kingdom; Cecily Forsyth, Gosford Hospital, Gosford, and Australasian Leukaemia and Lymphoma Group, Australia; and Jean-Jacques Kiladjian, Hôpital Saint-Louis, Paris, France.

Purpose Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET age 40 to 59 years and without high-risk factors or extreme thrombocytosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.8414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131PMC
August 2018
8 Reads

[Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Aug;26(4):1122-1128

Department of Hematology, China-Japan Friendship Hospital, Beijing100029, China.

Objective: To detect the JAK2, CALR and MPL gene mutations in patients with BCR/ABL1 negative chronic myeloproliferative diseases(BCR/ABL1-CMPD)and to evaluate their diagnostic value.

Methods: Two hundred and eight cases of BCR/ABL1-CMPD comprising of 146 cases of essential thrombocythemia(ET), 37 cases of polycythemia vera(PV)and 25 cases of primary myelofibrosis(PMF)from March 2012 to December 2015 were enrolled in the BCR/ABL1-CMPD, while 124 cases of secondary thrombocythemia and 73 cases of secondary polycythemia were enrolled in the control group. The genomic DNA and total RNA Were isolated from bone marrow or peripheral blood, then the exons 12 to 20 of JAK2 gene, exon 10 of MPL gene and exons 3 to 9 of CALR gene were analyzed by using DNA sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2018.04.030DOI Listing
August 2018
4 Reads

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Am J Hematol 2018 Nov 5;93(11):1347-1357. Epub 2018 Oct 5.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

In a 28-year period, 39 (7%) patients with chronic myelomonocytic leukemia (CMML) (median age 66 years, 64% male) underwent a splenectomy at our institution. Primary indications for splenectomy were refractory thrombocytopenia (36%), progressive spleen related symptoms (33%), emergent splenectomy for splenic rupture (21%), refractory anemia (8%), and prior to allogeneic stem cell transplant (3%). Eleven (28%) patients had anemia at the time of splenectomy, of which 3 (27%) were autoimmune. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196105PMC
November 2018
5 Reads

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.

Medicine (Baltimore) 2018 Jul;97(27):e11331

Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Rationale: The JAK2 V617F mutation is frequently found in ET, while it is rare in de novo AML. ET has a low frequency of leukemic transformation. Both secondary AML (sAML) from ET and AML with JAK2 V617F mutation have poor prognoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000011331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076173PMC
July 2018
10 Reads

Lung Abscess Remains a Life-Threatening Condition in Pediatrics - A Case Report.

J Crit Care Med (Targu Mures) 2017 Jul 19;3(3):123-127. Epub 2017 Aug 19.

Paediatrics Clinic 1 Tîrgu Mureş, Tîrgu Mureş, Romania.

Pulmonary abscess or lung abscess is a lung infection which destroys the lung parenchyma leading to cavitations and central necrosis in localised areas formed by thick-walled purulent material. It can be primary or secondary. Lung abscesses can occur at any age, but it seems that paediatric pulmonary abscess morbidity is lower than in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jccm-2017-0023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769901PMC
July 2017
8 Reads

Jak-2 mutation frequency in patients with thrombocytosis.

Caspian J Intern Med 2018 ;9(2):189-193

Department of Infectious Diseases and Clinical MicrobiologyMinistry of Health Bakırköy Sadi Konuk Training and Research Hospitalstanbul, Turkey.

Background: We aimed to investigate the etiologic causes and the existence of Janus kinase 2 mutation (JAK2) in cases with thrombocytosis.

Methods: In this retrospective study, patients who were admitted to hematology clinic with thrombocytosis between 2013 and 2015 were investigated in terms of the etiological causes of thrombocytosis and the existence of JAK2 mutation.

Results: We retrospectively evaluated 136 cases that underwent JAK2 mutation analysis due to ET preliminary diagnosis in our hematology clinic. Read More

View Article

Download full-text PDF

Source
http://caspjim.com/article-1-787-en.html
Publisher Site
http://dx.doi.org/10.22088/cjim.9.2.189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912229PMC
January 2018
2 Reads

[Investigation and treatment of prefibrotic/early primary myelofibrosis. A case study].

Orv Hetil 2018 Apr;159(15):603-609

II. Belgyógyászati Klinika, Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.

Moderate thrombocytosis can accompany several diseases (bleeding, inflammation, iron deficiency, or autoimmune diseases), but hematologic examination is strongly recommended in a patient with persistent platelet count above 450 G/L unless reactive origin can be confirmed. The 47-year-old woman's medical history included hypertonia, asthma bronchiale, and endometriosis. In March 2015, she underwent laboratory examination due to weight loss and lack of appetite. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/650.2018.30995DOI Listing
April 2018
4 Reads

Plateletpheresis: Nonoperative Management of Symptomatic Carotid Thrombosis in a Patient with Reactive Thrombocytosis.

World Neurosurg 2018 Jun 16;114:126-129. Epub 2018 Mar 16.

Neurosciences Critical Care, Department of Neurology, University of Chicago Medical Center, Chicago, Illinois, USA.

Background: The most common pathology associated with an intraluminal carotid thrombus is underlying atherosclerosis. In rare cases, it may be associated with thrombocytosis. Currently there are no clear recommendations for the treatment of ischemic stroke associated with thrombocytosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.03.075DOI Listing
June 2018
8 Reads

Blood calcium, glucose and haematology profiles of parturient bitches diagnosed with uterine inertia or obstructive dystocia.

Reprod Domest Anim 2018 Jun 14;53(3):680-687. Epub 2018 Mar 14.

Clinic of Reproductive Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

Bitches with dystocia most often present with clinical signs of uterine inertia (UI). The aetiology of myometrial dysfunction in most of these cases is still not elucidated. We compared blood ionized calcium (iCa) and glucose concentrations in bitches diagnosed with primary UI (PUI, n = 14), secondary UI (SUI, n = 6) or obstructive dystocia (OD, n = 6), and we described their haematology profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/rda.13157DOI Listing
June 2018
2 Reads

Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.

Hematology 2018 Oct 9;23(9):613-619. Epub 2018 Mar 9.

d Department of Pathology, Faculty of Medicine , Chiang-Mai University , Chiang Mai , Thailand.

Objectives: The primary objective was to determine the prevalence of calreticulin (CALR) mutation in patients with non-JAK2V617F mutated essential thrombocythemia (ET). The secondary objectives were to evaluate the accuracy of CALR mutation analysis by high-resolution melting (HRM) analysis and real-time polymerase chain reaction (PCR) compared with DNA sequencing and to compare clinical characteristics of CALR mutated and JAK2V617F mutated ET.

Methods: This was a prospective cohort study involving ET patients registered at Chiang Mai University in the period September 2015-September 2017 who were aged more than 2 years, and did not harbor JAK2V617F mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245332.2018.1448699DOI Listing
October 2018
5 Reads
1.190 Impact Factor

Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature.

Front Oncol 2018 19;8:32. Epub 2018 Feb 19.

Bone Marrow Transplantation Unit, Specialized Laboratories, Laboratory of Molecular Biology, National Cancer Institute (INCa), Rio de Janeiro, Brazil.

The genetic events associated with transformation of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML), particularly in the subgroup of essential thrombocythemia (ET) patients, remain incompletely understood. Deep studies using high-throughput methods might lead to a better understanding of genetic landscape of ET patients who transformed to sAML. We performed array-based comparative genomic hybridization (aCGH) and whole exome sequencing (WES) to analyze paired samples from ET and sAML phases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826070PMC
February 2018
9 Reads

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Int J Hematol 2018 Jun 20;107(6):673-680. Epub 2018 Feb 20.

Department of Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

The majority of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) harbor JAK2, CALR, or MPL mutations. We compared clinical manifestations of different subtypes of JAK2 and CALR mutations in Japanese patients with MPNs. Within our cohort, we diagnosed 166 patients as polycythemia vera (PV), 212 patients as essential thrombocythemia (ET), 23 patients as pre-primary myelofibrosis (PMF), 65 patients as overt PMF, and 27 patients as secondary myelofibrosis following the 2016 WHO criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-2421-7DOI Listing
June 2018
8 Reads

Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer.

World J Surg 2018 08;42(8):2542-2550

Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, 683-8504, Japan.

Background: Thrombocytosis develops in association with malignant tumors and may reflect the inflammation status in cancer patients. This study retrospectively investigated the prognostic significance of two platelet-based inflammatory indicators, the platelet × C-reactive protein multiplier value (P-CRP), and platelet-lymphocyte ratio (PLR), in gastric cancer patients.

Methods: The 453 enrolled patients had a histopathological diagnosis of gastric adenocarcinoma and underwent curative surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-018-4527-8DOI Listing
August 2018
1 Read

Necrotizing retinitis of multifactorial etiology.

Rom J Ophthalmol 2017 Jan-Mar;61(1):49-53

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

We present the case of a 73-year-old woman with osteoporosis, who presented to the emergency room with a sudden vision loss and ocular pain in the right eye, which appeared two days before. The patient mentioned loss of appetite, weight loss for three months and low fever for two weeks. Among the ophthalmological findings, the most important were panuveitis, and large confluent necrotic areas in the peripheral retina. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710053PMC
May 2018
9 Reads

Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.

Int J Lab Hematol 2018 Jun 10;40(3):320-325. Epub 2018 Feb 10.

Department of Hematology, Aarhus University Hospital, Aarhus C, Denmark.

Introduction: Diagnosing BCR-ABL negative myeloproliferative neoplasms (MPN) may be challenging due to overlapping features and lack of robust discriminatory parameters, especially between essential thrombocythemia (ET) and prefibrotic myelofibrosis (MF). Circulating immature hematopoietic cells are variably present in polycythemia vera (PV), ET, and MF. The C-type lectin hMICL is aberrantly expressed on hematopoietic stem cells in the majority of acute myeloid leukemia patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12787DOI Listing
June 2018
7 Reads

Thrombocytosis in children: Clinico-hematological profile from a single centre in Eastern India.

J Lab Physicians 2018 Jan-Mar;10(1):34-37

Department of Paediatrics, IMS and Sum Hospital, Bhubaneswar, Odisha, India.

Background And Objective: Thrombocytosis is not an uncommon finding in hemograms of children with an incidence of 6%-15% among hospitalized children. This study aims to determine the etiology of thrombocytosis and analyze various platelet parameters in children attending our hospital.

Materials And Methods: A prospective observational study was carried out in a tertiary care center in Odisha, in eastern part of India, for 6 months from July 2016 to December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JLP.JLP_90_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784290PMC
February 2018
2 Reads

Spurious Thrombocytosis in the Setting of Hemolytic Anemia and Microcytosis Secondary to Extensive Burn Injury

Turk J Haematol 2018 08 2;35(3):205-206. Epub 2018 Feb 2.

Temple University Hospital, Clinic of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania, USA

View Article

Download full-text PDF

Source
https://www.journalagent.com/z4/download_fulltext.asp?pdir=t
Publisher Site
http://dx.doi.org/10.4274/tjh.2017.0466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110454PMC
August 2018
3 Reads
0.340 Impact Factor

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.

Blood 2018 Feb 27;131(6):649-661. Epub 2017 Dec 27.

Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council Stem Cell Institute and.

Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). Multiple different mutations have been reported, but all result in a +1-bp frameshift and generate a novel protein C terminus. In this study, we generated a conditional mouse knockin model of the most common CALR mutation, a 52-bp deletion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-09-806356DOI Listing
February 2018
18 Reads

Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.

World J Urol 2018 Mar 18;36(3):417-425. Epub 2017 Dec 18.

Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK.

Purpose: To test the hypothesis that cytoreductive nephrectomy (CN) improves overall survival (OS) of patients with synchronous metastatic renal cell carcinoma (mRCC), who subsequently receive targeted therapies (TT).

Methods: We identified 261 patients who received TT for synchronous mRCC with or without prior CN. To achieve balance in baseline characteristics between groups, we used the inverse probability of treatment weighting (IPTW) method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-017-2154-xDOI Listing
March 2018
4 Reads

Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.

Eur J Haematol 2018 Mar 5;100(3):286-293. Epub 2018 Jan 5.

Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Objective: We aimed to determine hemostatic changes and characterize the procoagulant potential among patients with reactive thrombocytosis (RT).

Methods: Sixty patients with RT (median platelet count 718 × 10 /L) and 20 healthy persons were tested for complete blood count, C-reactive protein, von Willebrand factor (VWF), factor VIII and fibrinogen, and thrombin generation. Platelet studies, including light transmission aggregometry and Cone and Plate(let) Analyzer, were also conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13012DOI Listing
March 2018
11 Reads

POEMS Syndrome: Diagnosis and Investigative Work-up.

Hematol Oncol Clin North Am 2018 02;32(1):119-139

Division of Hematology, Department of Medicine, Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis, and Castleman disease is the first step in managing the disease. Increased blood levels of vascular endothelial growth factor are usually confirmatory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.09.010DOI Listing
February 2018
6 Reads

[Thrombocytosis and thrombocytopenia - background and clinical relevance].

Dtsch Med Wochenschr 2017 Nov 16;142(23):1732-1743. Epub 2017 Nov 16.

Due to the central role of platelets in hemostasis, the clinical relevance of quantitative changes in platelet counts (< 150 G/l or > 450 G/l) may be significant. Thrombopoesis (= production of platelets) occurs in the bone marrow, and the hormone thrombopoetin takes control on its regulation.In thrombocytosis, primary causes have to be distinguished from the far more common reactive (= secondary) reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0042-111096DOI Listing
November 2017
15 Reads

Clinical and laboratory assessment of a patient with thrombocytosis.

Br J Hosp Med (Lond) 2017 Oct;78(10):558-564

Core Medical Trainee, Department of Haematology, Mater Misercordiae University Hospital, Dublin.

Elevated platelet counts are frequently encountered in hospital medicine and arise from both physiological and pathological mechanisms. Thrombocytosis may be secondary, reflecting an inflammatory state, iron deficiency, recent surgery or point towards an underlying neoplasm. Thrombocytosis may be the presenting sign of solid tumours and haematological conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/hmed.2017.78.10.558DOI Listing
October 2017
5 Reads

A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Leuk Res 2017 10 31;61:89-95. Epub 2017 Aug 31.

University of Utah School of Medicine, Division of Hematology, 30 North 1900 East, Salt Lake City, UT 84132, USA. Electronic address:

Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2 mutation. The study had a standard 3+3 dose-escalation design to define the maximum-tolerated dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.08.010DOI Listing
October 2017
47 Reads
2 Citations
2.351 Impact Factor

Thrombocytosis in 715 Dogs (2011-2015).

J Vet Intern Med 2017 Nov 12;31(6):1691-1699. Epub 2017 Sep 12.

Department of Veterinary Administration, College of Veterinary Medicine, Purdue University, West Lafayette, IN.

Background: Thrombocytosis is a hematologic abnormality in dogs that has been associated with various neoplastic, metabolic, and inflammatory conditions.

Objective: To classify thrombocytosis in dogs based on severity and evaluate whether there are associations between severity and underlying disease processes.

Animals: Seven hundred and fifteen dogs with thrombocytosis and 1,430 dogs with normal numbers of platelets. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvim.14831
Publisher Site
http://dx.doi.org/10.1111/jvim.14831DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697177PMC
November 2017
23 Reads

Management of Nephrotic Syndrome: A Case Report from Lao PDR.

Blood Purif 2017 5;44 Suppl 1:31-34. Epub 2017 Sep 5.

Hemodialysis Center and Division of Nephrology, Mittaphab Hospital, Vientiane, Lao PDR.

We report the case of a 23-year-old woman with a 2-week history of swelling around the eyes and both legs, and generalized body swelling. She had a history of chronic constipation and poor diet but no fever, recent illnesses, or hematuria. Examination revealed bilateral pedal edema and mild ascites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000479615DOI Listing
July 2018
10 Reads

Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.

Am J Case Rep 2017 Sep 1;18:945-948. Epub 2017 Sep 1.

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

BACKGROUND Clopidogrel is commonly used in the prevention and treatment of cardiovascular events. However, despite clopidogrel treatment, some patients experience recurrent ischemic events. CASE REPORT We present the case of a 58-year-old man with polycythemia vera and concomitant thrombocytosis who suffered 6 episodes of cerebral infarctions and 1 myocardial infarction, despite treatment with clopidogrel. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590514PMC
September 2017
7 Reads

Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Nat Commun 2017 08 21;8(1):310. Epub 2017 Aug 21.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates with worsened patient survival. Tumor cell interaction with various cellular components of the tumor microenvironment including platelets is crucial for tumor growth and metastasis. Although it is known that platelets can infiltrate into tumor tissue, secrete pro-angiogenic and pro-tumorigenic factors and thereby increase tumor growth, the precise molecular interactions between platelets and metastatic cancer cells are not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-00411-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566477PMC
August 2017
39 Reads

Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma.

Clin Genitourin Cancer 2017 12 19;15(6):e1039-e1045. Epub 2017 Jun 19.

Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address:

Purpose: The purpose of this study was to evaluate the predictive and prognostic role of preoperative thrombocytosis (TC) in upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) in a large multi-institutional cohort of patients.

Methods: Records of 2492 patients undergoing RNU for non-metastatic UTUC between 1990 and 2008 were retrospectively analyzed. Preoperative TC was defined as a platelet count > 400 × 10/L, irrespective of gender type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.06.003DOI Listing
December 2017
13 Reads

Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma.

Pathology 2017 Aug 28;49(5):471-475. Epub 2017 Jun 28.

Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Paraneoplastic thrombocytosis has been associated with adverse outcomes in several cancers, but has not been described in oesophageal adenocarcinoma. The aim of our study was to examine the prognostic value of platelet counts in patients with oesophageal adenocarcinoma. A cohort of 584 patients who underwent oesophagectomy for oesophageal adenocarcinoma was identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2017.04.001DOI Listing
August 2017
6 Reads

Early pulmonary response is critical for extra-pulmonary carbon nanoparticle mediated effects: comparison of inhalation versus intra-arterial infusion exposures in mice.

Part Fibre Toxicol 2017 06 20;14(1):19. Epub 2017 Jun 20.

Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum München, German Research Center for Environmental Health, D85764, Neuherberg, Germany.

Background: The death toll associated with inhaled ambient particulate matter (PM) is attributed mainly to cardio-vascular rather than pulmonary effects. However, it is unclear whether the key event for cardiovascular impairment is particle translocation from lung to circulation (direct effect) or indirect effects due to pulmonary particle-cell interactions. In this work, we addressed this issue by exposing healthy mice via inhalation and intra-arterial infusion (IAI) to carbon nanoparticles (CNP) as surrogate for soot, a major constituent of (ultrafine) urban PM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12989-017-0200-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480131PMC
June 2017
12 Reads

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Leuk Res 2017 09 30;60:11-17. Epub 2017 May 30.

Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia.

Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100mg and 200mg) for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The primary endpoint for PV was overall response rate (ORR), defined as the proportion of patients with hematocrit <45%, white blood cell count <10×10/L, platelet count ≤400×10/L, and resolution of palpable splenomegaly, each lasting ≥4 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.002DOI Listing
September 2017
14 Reads

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Leukemia 2017 12 31;31(12):2726-2731. Epub 2017 May 31.

CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/leu.2017.169DOI Listing
December 2017
48 Reads

Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.

Hematol Oncol 2018 Feb 29;36(1):336-339. Epub 2017 May 29.

Hematology Laboratory, Henri Mondor Hospital, AP-HP, Créteil, France.

Myeloproliferative neoplasms are characterized by transduction pathway recognized as mutually exclusive molecular abnormalities such as BCR-ABL translocation, JAK2V617F or JAK2 exon 12 mutations, MPL w515, and CALR mutations. However, in some rare cases, associations of such mutations are found in 1 patient. This can be related to 2 pathologies (at least 2 different clones harboring 2 mutations) or associated mutations in 1 clone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2431DOI Listing
February 2018
17 Reads

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Cancer Med 2017 Jun 23;6(6):1233-1239. Epub 2017 May 23.

Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy.

Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463060PMC
June 2017
38 Reads

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Leuk Lymphoma 2017 11 9;58(11):2582-2587. Epub 2017 May 9.

a Service d'Hématologie , Institut de Cancéro-Hématologie, CHRU de Brest , Brest , France.

Many case reports have indicated the occurrence of monoclonal gammopathy of uncertain significance (MGUS) or multiple myeloma (MM) in patients with Ph-negative myeloproliferative neoplasms (MPN), but few cohorts of patients have been published. This study concerns 667 patients newly diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET) who were tested for monoclonal (M) protein at diagnosis (13.9% of patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1312380DOI Listing
November 2017
74 Reads

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.

Oncotarget 2017 May;8(20):33796-33806

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Purpose: Genetic alterations such as activating KRAS and/or inactivating TP53 are thought to be the most common drivers to tumorigenesis. Therefore, we assessed phase I cancer patients with KRAS+/TP53+ mutations.

Results: Approximately 8% of patients referred to phase I clinical trials harbored concurrent KRAS and TP53 mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.16840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464912PMC
May 2017
22 Reads

Thrombocytosis in a patient with upper gastrointestinal bleeding.

Intractable Rare Dis Res 2017 Feb;6(1):69-71

Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China.

Reported here is a case of upper gastrointestinal bleeding secondary to a peptic ulcer involving an extremely high platelet count of 989 × 10/L. Myeloproliferative neoplasms were ruled out on the basis of gene mutation testing and a bone marrow biopsy. After the cessation of index bleeding, the platelet count decreased markedly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5582/irdr.2016.01080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359359PMC
February 2017
10 Reads

POEMS Syndrome: an Enigma.

Curr Hematol Malig Rep 2017 04;12(2):85-95

Division of Hematology, Medicine and Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

POEMS syndrome is a paraneoplastic disorder secondary to an underlying plasma cell dyscrasia. By definition, all patients with POEMS syndrome must display polyneuropathy and monoclonal plasma cell disorder. In addition, at least one major criterion (Castleman's disease, sclerotic bone lesions, or vascular endothelial growth factor elevation) and one minor criterion (organomegaly, extravascular volume overload, endocrinopathy, skin changes, papilledema, thrombocytosis, or polycythemia) are required for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0367-0DOI Listing
April 2017
8 Reads

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.

Ann Hematol 2017 May 28;96(5):733-738. Epub 2017 Feb 28.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA.

New automated hematology analyzers have led to the availability of novel hematological parameters, including the immature platelet fraction (IPF) and the immature reticulocyte fraction (IRF), both of potential interest in patients with myeloproliferative neoplasms (MPNs). We performed a prospective analysis of 217 patients with MPN, including 32 (15%) with essential thrombocythemia (ET), 43 (20%) with polycythemia vera (PV), and 142 (65%) with myelofibrosis (MF); the IPF and IRF were measured by the Sysmex XN analyzer. As compared to patients with ET, both a higher IPF and IRF were observed among patients with PV and MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-2956-3DOI Listing
May 2017
48 Reads

Prognostic relevance of hematological profile before resection for colorectal liver metastases.

J Surg Res 2016 12 12;206(2):498-506. Epub 2016 Aug 12.

Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany.

Background: Although alterations of hematological profile and especially elevated platelet counts were reported to influence survival in primary colorectal cancer, its prognostic relevance before the surgical treatment of colorectal liver metastases (CLM) is mainly unclear. Therefore, the aim of this study was to analyze the impact of these factors on overall survival following liver resection of CLM.

Materials And Methods: The surgical treatment of primary CLM between 1994 and 2012 in 983 patients was retrospectively analyzed using univariable and multivariable Cox regression models. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00224804163027
Publisher Site
http://dx.doi.org/10.1016/j.jss.2016.08.012DOI Listing
December 2016
14 Reads

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

Blood Cancer J 2016 11 4;6(11):e493. Epub 2016 Nov 4.

FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.

We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bcj.2016.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148051PMC
November 2016
7 Reads

Occlusive Nonvasculitic Vasculopathy.

Am J Dermatopathol 2017 Sep;39(9):637-662

*Associate Staff of the Department of Dermatology, Department of Dermatology, Hospital Universitario de la Princesa, Universidad Autónoma, Madrid, Spain; †Associate Staff of the Department of Dermatology, Department of Dermatology, Fundación Jiménez Diaz, Universidad Autónoma, Madrid, Spain; ‡Director of Dermatopathology, Department of Dermatology, Hospital Clínico Universitario, Salamanca, Spain; §Director of Dermatopathology, Dermatopathology Research Unit, Medical University of Graz, Graz, Austria; ¶Director of Dermatopathology, Dermatopathologie Laboratory, Friedrichschafen, Germany; and ‖Chairman of the Department of Dermatology, Department of Dermatology, Hospital Clínico Universitario, Salamanca, Spain.

We review the most characteristic clinical and histopathologic findings of the cutaneous manifestations of the occlusive nonvasculitic vasculopathic disorders. Clinically, most of these conditions are characterized by retiform purpura. Histopathologic findings consist of occlusion of the vessel lumina with no vasculitis. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000372-201709000-0000
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000000766DOI Listing
September 2017
61 Reads

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

Int J Cancer 2017 Jan 17;140(1):208-215. Epub 2016 Oct 17.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

Patients ≥65 years with cancer remain underrepresented in clinical trials, particularly in phase I clinical trials. We analyzed the clinical course of patients ≥65 years treated on phase I clinical trials with particular emphasis on toxicities. We identified 347 consecutive patients ≥65 years with advanced cancer in our phase I clinic from 01/2004-12/2009 and analyzed disease characteristics, toxicities, survival and response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30417DOI Listing
January 2017
16 Reads

Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera.

Osteoporos Int 2017 02 13;28(2):677-685. Epub 2016 Oct 13.

Department of Haematology, Odense University Hospital, Sdr. Boulevard 29, DK-5000, Odense, Denmark.

In this cross-sectional study of 45 patients with myeloproliferative neoplasms, we found no evidence of secondary osteoporosis.

Introduction: Patients with essential thrombocythemia (ET) and polycythaemia vera (PV) are at increased risk of fractures but the underlying mechanisms have not been settled. We conducted a study to assess bone mineral density, microarchitecture, estimated bone strength and global bone turnover in 45 patients with ET or PV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-016-3788-zDOI Listing
February 2017
5 Reads